As of November 10, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of NovoCure Ltd. The largest reported stake is Soleus Capital Master Fund, L.P.'s, at 8.1%. 10 filings are on record since July 7, 2025 (Schedule 13G/A, November 9, 2026).
Sell to companies like NovoCure Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Soleus Capital Master Fund, L.P. · Sole voting: 0 · Shared voting: 9,425,776 · Sole dispositive: 0 · Shared dispositive: 9,425,776 · SCHEDULE 13G/A, 2026-11-09
- · Holder: Soleus Capital Master Fund, L.P. · Percent: 9.1% · SCHEDULE 13G/A
- · Reporting person: Vanguard Portfolio Management · Sole voting: 88,293 · Shared voting: 0 · Sole dispositive: 6,339,994 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-28
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-26
- · Holder: Soleus Capital Master Fund, L.P. · Percent: 7.6% · SCHEDULE 13G/A
NovoCure Ltd has 10 Schedule 13D or 13G filings on record since 2025-07-07. 2 holders' latest filing reports 5% or more of ordinary shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 8.1% | 9,425,776 | SCHEDULE 13G/A, 2026-11-09 | 2026-09-30 |
| Vanguard Portfolio Management | 5.57% | 6,339,994 | SCHEDULE 13G, 2026-04-28 | 2026-03-31 |
| Capital World Investors | 1.8% | 2,000,000 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Capital International Investors | 0% | 0 | SCHEDULE 13G/A, 2025-07-07 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind NovoCure Ltd and the warning signs.
Free to see. No signup.
Keep reading
More on NovoCure Ltd and the records around it.
NovoCure Ltd elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
Watch NovoCure Ltd
Get an email when NovoCure Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NovoCure Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NovoCure Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NovoCure Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 0 | 9,425,776 | 0 | 9,425,776 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital, LLC | 0 | 9,425,776 | 0 | 9,425,776 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital Group, LLC | 0 | 9,425,776 | 0 | 9,425,776 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus Capital Management, L.P. | 0 | 9,425,776 | 0 | 9,425,776 | SCHEDULE 13G/A, 2026-11-09 |
| Soleus GP, LLC | 0 | 9,425,776 | 0 | 9,425,776 | SCHEDULE 13G/A, 2026-11-09 |
| Levy Guy | 0 | 9,425,776 | 0 | 9,425,776 | SCHEDULE 13G/A, 2026-11-09 |
| Vanguard Portfolio Management | 88,293 | 0 | 6,339,994 | 0 | SCHEDULE 13G, 2026-04-28 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
The latest filing identifies NovoCure Ltd by CUSIP G6674U108 and gives its principal executive office as No. 4 The Forum, Grenville Street, St. Helier (SCHEDULE 13G/A, 2026-11-09).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-07 | Capital International Investors | 0% | SCHEDULE 13G/A |
| 2025-08-05 | Soleus Capital Master Fund, L.P. | 6.2% | SCHEDULE 13G/A |
| 2025-08-13 | Capital World Investors | 5.7% | SCHEDULE 13G |
| 2025-11-07 | Soleus Capital Master Fund, L.P. | 8.6% | SCHEDULE 13G/A |
| 2025-11-13 | Capital World Investors | 1.8% | SCHEDULE 13G/A |
| 2026-02-12 | Soleus Capital Master Fund, L.P. | 7.6% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-28 | Vanguard Portfolio Management | 5.57% | SCHEDULE 13G |
| 2026-05-08 | Soleus Capital Master Fund, L.P. | 9.1% | SCHEDULE 13G/A |
| 2026-11-09 | Soleus Capital Master Fund, L.P. | 8.1% | SCHEDULE 13G/A |
Questions about who owns NovoCure Ltd
Who owns NovoCure Ltd?
On this page, 2 holders' latest ownership filings report 5% or more of NovoCure Ltd: Soleus Capital Master Fund, L.P. (8.1%, Schedule 13G/A, filed 2026-11-09) and Vanguard Portfolio Management (5.57%, Schedule 13G, filed 2026-04-28).
Who are the largest shareholders of NovoCure Ltd?
By the share each holder's latest filing reports, the largest holders of NovoCure Ltd on this page are Soleus Capital Master Fund, L.P. (8.1%) and Vanguard Portfolio Management (5.57%).
When did Soleus Capital Master Fund, L.P. buy into NovoCure Ltd?
The filings give report dates, not purchase dates. The earliest filing from Soleus Capital Master Fund, L.P. on this page is the Schedule 13G/A, filed 2025-08-05, reporting 6.2%; its latest, Schedule 13G/A filed 2026-11-09, reports 8.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for NovoCure Ltd
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 9, 2026 | Leadership change: Timothy Scannell departs, Director | — | Leadership changes | Source |
| April 24, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for NovoCure Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.